bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 3 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Authors: Kim Mickey K. , Osada Takuya , Barry William T. , Yang Xiao Yi , Freedman Jennifer A. , Tsamis Katherine A. , Datto Michael , Clary Bryan M. , Clay Timothy , Morse Michael A. , Febbo Philip G. , Lyerly H. Kim , Hsu David S.
Published: April 2023

PDF file - 39K, Tumor growth inhibition of patient derived colorectal cancer explant to oxaliplatin.
Supplementary Materials and Methods from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
Authors: Kim Mickey K. , Osada Takuya , Barry William T. , Yang Xiao Yi , Freedman Jennifer A. , Tsamis Katherine A. , Datto Michael , Clary Bryan M. , Clay Timothy , Morse Michael A. , Febbo Philip G. , Lyerly H. Kim , Hsu David S.
Published: April 2023

PDF file - 124K
Supplementary Figure S4ABC from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Authors: Raina Deepak , Kosugi Michio , Ahmad Rehan , Panchamoorthy Govind , Rajabi Hasan , Alam Maroof , Shimamura Takeshi , Shapiro Geoffrey I. , Supko Jeffrey , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplementary Figure S4ABC from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Supplementary Figure 1 from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Authors: Raina Deepak , Kosugi Michio , Ahmad Rehan , Panchamoorthy Govind , Rajabi Hasan , Alam Maroof , Shimamura Takeshi , Shapiro Geoffrey I. , Supko Jeffrey , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplementary Figure 1 from Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Supplementary Figure 3 from MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells In vitro and In vivo by Downregulating Growth and DNA Repair Signals
Authors: Marampon Francesco , Gravina Giovanni Luca , Di Rocco Agnese , Bonfili Pierluigi , Di Staso Mario , Fardella Caterina , Polidoro Lorella , Ciccarelli Carmela , Festuccia Claudio , Popov Vladimir M. , Pestell Richard G. , Tombolini Vincenzo , Zani Bianca Maria
Published: April 2023

Supplementary Figure 3 from MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells In vitro and In vivo by Downregulating Growth and DNA Repair Signals
Supplementary Figure 3 from In Situ Vaccination with CD204 Gene-Silenced Dendritic Cell, not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer
Authors: Guo Chunqing , Yi Huanfa , Yu Xiaofei , Zuo Daming , Qian Jie , Yang Gary , Foster Barbara A. , Subjeck John R. , Sun Xiaolei , Mikkelsen Ross B. , Fisher Paul B. , Wang Xiang-Yang
Published: April 2023

PDF file, 1337K, The effect of combined RT and in situ DC vaccination on tumor-infiltrating CD4+ and CD11c+ cells.
Supplementary Figure 3 from Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol
Authors: Riffell Jenna L. , Jänicke Reiner U. , Roberge Michel
Published: April 2023

Supplementary Figure 3 from Caspase-3–Dependent Mitotic Checkpoint Inactivation by the Small-Molecule Inducers of Mitotic Slippage SU6656 and Geraldol
Supplementary Table 1 from The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo
Authors: Menezes Daniel L. , Taverna Pietro , Jensen Michael R. , Abrams Tinya , Stuart Darrin , Yu Guoying Karen , Duhl David , Machajewski Timothy , Sellers William R. , Pryer Nancy K. , Gao Zhenhai
Published: April 2023

PDF file - 41K
Supplementary Figure 4 from Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer
Authors: Li Jing , Cao Bo , Liu Xichun , Fu Xueqi , Xiong Zhenggang , Chen Li , Sartor Oliver , Dong Yan , Zhang Haitao
Published: April 2023

Supplementary Figure 4 from Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer
Supplementary Figure 2 from Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer
Authors: Li Jing , Cao Bo , Liu Xichun , Fu Xueqi , Xiong Zhenggang , Chen Li , Sartor Oliver , Dong Yan , Zhang Haitao
Published: April 2023

Supplementary Figure 2 from Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer
Supplementary Figure 2 from Selective Targeting of Interferon γ to Stromal Fibroblasts and Pericytes as a Novel Therapeutic Approach to Inhibit Angiogenesis and Tumor Growth
Authors: Bansal Ruchi , Tomar Tushar , Östman Arne , Poelstra Klaas , Prakash Jai
Published: April 2023

PDF file, 660K, Effects of pPB-HSA-IFNγ in 3T3 fibroblasts on collagen-I expression, caspase 3/7 activity and cell proliferation in vitro.
Supplementary Figure 1 from Selective Targeting of Interferon γ to Stromal Fibroblasts and Pericytes as a Novel Therapeutic Approach to Inhibit Angiogenesis and Tumor Growth
Authors: Bansal Ruchi , Tomar Tushar , Östman Arne , Poelstra Klaas , Prakash Jai
Published: April 2023

PDF file, 2841K, Immunohistochemical staining of the PDGFβR and IFNγR in subcutaneous B16 melanoma tumors and other organs in mice.
Supplementary Figure 1 from Spliceosome-Mediated RNA Trans-Splicing Facilitates Targeted Delivery of Suicide Genes to Cancer Cells
Authors: Gruber Christina , Gratz Iris K. , Murauer Eva M. , Mayr Elisabeth , Koller Ulrich , Bruckner-Tuderman Leena , Meneguzzi Guerrino , Hintner Helmut , Bauer Johann W.
Published: April 2023

Supplementary Figure 1 from Spliceosome-Mediated RNA Trans-Splicing Facilitates Targeted Delivery of Suicide Genes to Cancer Cells
Supplementary Figure 1 from SAR131675, a Potent and Selective VEGFR-3–TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities
Authors: Alam Antoine , Blanc Isabelle , Gueguen-Dorbes Geneviève , Duclos Olivier , Bonnin Jacques , Barron Pauline , Laplace Marie-Claude , Morin Gaelle , Gaujarengues Florence , Dol Frédérique , Hérault Jean-Pascal , Schaeffer Paul , Savi Pierre , Bono Françoise
Published: April 2023

PDF file - 194K, This files shows the effect of SAR131675 different variants of human VEGFR-3 and on murin VEGFR-3. It also shows example of results obtained with sunitinib on VEGFRs and on lymphatic cells proliferation
Supplementary Tables 1 - 3 from TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
Authors: Fitzgerald Daniel P. , Emerson David L. , Qian Yongzhen , Anwar Talha , Liewehr David J. , Steinberg Seth M. , Silberman Sandra , Palmieri Diane , Steeg Patricia S.
Published: April 2023

PDF file, 74KB, Pharmacokinetics for TPI-287 in rodents.
Supplementary Figure Legend from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents
Authors: Sharma Sharad , Zeng Jun-Ying , Zhuang Chun-Mei , Zhou Yong-Qing , Yao Hang-Ping , Hu Xing , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

PDF file - 71K
Supplementary Figure 3 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents
Authors: Sharma Sharad , Zeng Jun-Ying , Zhuang Chun-Mei , Zhou Yong-Qing , Yao Hang-Ping , Hu Xing , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

PDF file - 59K, Figure S3: Effect of PHA665752, Compound-I, and BMS-777607 on induction of polyploidy in breast cancer cells.
Supplementary Figure 5 from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
Authors: Nam Hyun-Jin , Im Seock-Ah , Oh Do-Youn , Elvin Paul , Kim Hwang-Phill , Yoon Young-Kwang , Min Ahrum , Song Sang-Hyun , Han Sae-Won , Kim Tae-You , Bang Yung-Jue
Published: April 2023

PDF file - 96K, Downregulation of thymidylate synthase (TS) by saracatinib
Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents
Authors: Sharma Sharad , Zeng Jun-Ying , Zhuang Chun-Mei , Zhou Yong-Qing , Yao Hang-Ping , Hu Xing , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

PDF file - 68K, Figure S2: Effect of BMS-777607 on breast cancer cell growth and apoptotic death.
Supplementary Figure 4 from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
Authors: Nam Hyun-Jin , Im Seock-Ah , Oh Do-Youn , Elvin Paul , Kim Hwang-Phill , Yoon Young-Kwang , Min Ahrum , Song Sang-Hyun , Han Sae-Won , Kim Tae-You , Bang Yung-Jue
Published: April 2023

PDF file - 135K, Treatment of saracatinib in LS174T and SKBR3 cells
Supplementary Table 4 from Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
Authors: Giles Keith M. , Kalinowski Felicity C. , Candy Patrick A. , Epis Michael R. , Zhang Priscilla M. , Redfern Andrew D. , Stuart Lisa M. , Goodall Gregory J. , Leedman Peter J.
Published: April 2023

PDF - 771KB, Supplementary Table S4. Functional pathways associated with acquired erlotinib resistance in HNC and NSCLC.
Supplementary Table 2 from Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
Authors: Giles Keith M. , Kalinowski Felicity C. , Candy Patrick A. , Epis Michael R. , Zhang Priscilla M. , Redfern Andrew D. , Stuart Lisa M. , Goodall Gregory J. , Leedman Peter J.
Published: April 2023

PDF - 313KB, Supplementary Table S2. List of genes downregulated in HN5-ER cells relative to HN5 cells.
Supplementary Figure 1 from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
Authors: Nam Hyun-Jin , Im Seock-Ah , Oh Do-Youn , Elvin Paul , Kim Hwang-Phill , Yoon Young-Kwang , Min Ahrum , Song Sang-Hyun , Han Sae-Won , Kim Tae-You , Bang Yung-Jue
Published: April 2023

PDF file - 114K, Chemical structures of investigated molecules in this article
Supplementary Figure 3 from Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
Authors: Giles Keith M. , Kalinowski Felicity C. , Candy Patrick A. , Epis Michael R. , Zhang Priscilla M. , Redfern Andrew D. , Stuart Lisa M. , Goodall Gregory J. , Leedman Peter J.
Published: April 2023

PDF - 59KB, Supplementary Figure S3. Inhibition of Axl activity in HN5-ER cells and EGFR activity in HN5 cells with the Axl inhibitor R428.
Supplementary Figure 2 from Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
Authors: Giles Keith M. , Kalinowski Felicity C. , Candy Patrick A. , Epis Michael R. , Zhang Priscilla M. , Redfern Andrew D. , Stuart Lisa M. , Goodall Gregory J. , Leedman Peter J.
Published: April 2023

PDF - 27KB, Supplementary Figure S2. Immunoblotting analysis of EGFR, Akt and E-cadherin in HN5-ER2 cells.
Supplementary Figure 1 from Apigenin Induces Apoptosis in Human Leukemia Cells and Exhibits Anti-Leukemic Activity In Vivo
Authors: Budhraja Amit , Gao Ning , Zhang Zhuo , Son Young-Ok , Cheng Senping , Wang Xin , Ding Songze , Hitron Andrew , Chen Gang , Luo Jia , Shi Xianglin
Published: April 2023

PDF file - 2.7MB
Supplementary Figures 1-5 from Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2
Authors: Bid Hemant K. , Zhan Jun , Phelps Doris A. , Kurmasheva Raushan T. , Houghton Peter J.
Published: April 2023

PDF file - 3.2MB
Supplementary Methods, Figures 1-4 from Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells
Authors: Liu Yan , Sun Shi-Yong , Owonikoko Taofeek K. , Sica Gabriel L. , Curran Walter J. , Khuri Fadlo R. , Deng Xingming
Published: April 2023

PDF file - 476K
Supplementary Figure Legends from GX15-070 (Obatoclax) Induces Apoptosis and Inhibits Cathepsin D- and L–Mediated Autophagosomal Lysis in Antiestrogen-Resistant Breast Cancer Cells
Authors: Schwartz-Roberts Jessica L. , Shajahan Ayesha N. , Cook Katherine L. , Wärri Anni , Abu-Asab Mones , Clarke Robert
Published: April 2023

Supplementary Figure Legends PDF file - 65K, Legends for supplemental figures
Supplementary Figure 4 from GX15-070 (Obatoclax) Induces Apoptosis and Inhibits Cathepsin D- and L–Mediated Autophagosomal Lysis in Antiestrogen-Resistant Breast Cancer Cells
Authors: Schwartz-Roberts Jessica L. , Shajahan Ayesha N. , Cook Katherine L. , Wärri Anni , Abu-Asab Mones , Clarke Robert
Published: April 2023

Supplementary Figure 4 PDF file - 29K, Knockdown of BECN1 by siRNA does not prevent GX-mediated inhibition of cell density
Supplementary Figure Legends 1-6 from Tumor Suppressor MicroRNA-493 Decreases Cell Motility and Migration Ability in Human Bladder Cancer Cells by Downregulating RhoC and FZD4
Authors: Ueno Koji , Hirata Hiroshi , Majid Shahana , Yamamura Soichiro , Shahryari Varahram , Tabatabai Z. Laura , Hinoda Yuji , Dahiya Rajvir
Published: April 2023

PDf file - 92K
Supplementary Figure 1 from Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents
Authors: Liang Zheng D. , Long Yan , Tsai Wen-Bin , Fu Siqing , Kurzrock Razelle , Gagea-Iurascu Mihai , Zhang Fan , Chen Helen H.W. , Hennessy Bryan T. , Mills Gordon B. , Savaraj Niramol , Kuo Macus Tien
Published: April 2023

PDF file, 94K, Fig. S1. No induction of ATP7A/ATP7B in cDDPR vs cDDPS cells by TM as determined by RPA (A) and Western blotting (B).
Supplementary Figure 1 from Antitumor Activity of Triolimus: A Novel Multidrug-Loaded Micelle Containing Paclitaxel, Rapamycin, and 17-AAG
Authors: Hasenstein Jason R. , Shin Ho-Chul , Kasmerchak Kelsey , Buehler Darya , Kwon Glen S. , Kozak Kevin R.
Published: April 2023

PDF file, 320K, Acute histopathologic effects of paclitaxel-containing micelles and Triolimus.
Supplementary Figure Legends 1-5 from Inhibition of p38 MAPK-Dependent Excision Repair Cross-Complementing 1 Expression Decreases the DNA Repair Capacity to Sensitize Lung Cancer Cells to Etoposide
Authors: Tsai Min-Shao , Weng Shao-Hsing , Chen Huang-Jen , Chiu Yu-Fan , Huang Yu-Ching , Tseng Sheng-Chieh , Kuo Ya-Hsun , Lin Yun-Wei
Published: April 2023

PDF file - 97K
Supplementary Figure 5 from Inhibition of p38 MAPK-Dependent Excision Repair Cross-Complementing 1 Expression Decreases the DNA Repair Capacity to Sensitize Lung Cancer Cells to Etoposide
Authors: Tsai Min-Shao , Weng Shao-Hsing , Chen Huang-Jen , Chiu Yu-Fan , Huang Yu-Ching , Tseng Sheng-Chieh , Kuo Ya-Hsun , Lin Yun-Wei
Published: April 2023

PDF file - 369K
Supplementary Figure 2 from Inhibition of p38 MAPK-Dependent Excision Repair Cross-Complementing 1 Expression Decreases the DNA Repair Capacity to Sensitize Lung Cancer Cells to Etoposide
Authors: Tsai Min-Shao , Weng Shao-Hsing , Chen Huang-Jen , Chiu Yu-Fan , Huang Yu-Ching , Tseng Sheng-Chieh , Kuo Ya-Hsun , Lin Yun-Wei
Published: April 2023

PDF file - 450K
Supplementary Figure Legend from Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage
Authors: Miljkovic-Licina Marijana , Hammel Philippe , Garrido-Urbani Sarah , Lee Boris P.-L. , Meguenani Mehdi , Chaabane Chiraz , Bochaton-Piallat Marie-Luce , Imhof Beat A.
Published: April 2023

PDF file - 88K
Supplementary Table 3 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
Authors: Hook Kenneth E. , Garza Scott J. , Lira Maruja E. , Ching Keith A. , Lee Nathan V. , Cao Joan , Yuan Jing , Ye Jingjing , Ozeck Mark , Shi Stephanie T. , Zheng Xianxian , Rejto Paul A. , Kan Julie L.C. , Christensen James G. , Pavlicek Adam
Published: April 2023

PDF file - 162K
Supplementary Figure 4 from Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage
Authors: Miljkovic-Licina Marijana , Hammel Philippe , Garrido-Urbani Sarah , Lee Boris P.-L. , Meguenani Mehdi , Chaabane Chiraz , Bochaton-Piallat Marie-Luce , Imhof Beat A.
Published: April 2023

PDF file - 2824K, Structural domains of Olfml3 protein
Supplementary Figure 2 from Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage
Authors: Miljkovic-Licina Marijana , Hammel Philippe , Garrido-Urbani Sarah , Lee Boris P.-L. , Meguenani Mehdi , Chaabane Chiraz , Bochaton-Piallat Marie-Luce , Imhof Beat A.
Published: April 2023

PDF file - 589K, Olfml3 silencing, production of rOlfml3-FLAG and in vitro wound-healing assay using anti-Olfml3 antibodies
Supplementary Figure Legends 1-3, Table Legends 1-4 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
Authors: Hook Kenneth E. , Garza Scott J. , Lira Maruja E. , Ching Keith A. , Lee Nathan V. , Cao Joan , Yuan Jing , Ye Jingjing , Ozeck Mark , Shi Stephanie T. , Zheng Xianxian , Rejto Paul A. , Kan Julie L.C. , Christensen James G. , Pavlicek Adam
Published: April 2023

PDF file - 67K
Supplementary Figure 6 from Antitumor Mechanisms of Targeting the PDK1 Pathway in Head and Neck Cancer
Authors: Bhola Neil E. , Freilino Maria L. , Joyce Sonali C. , Sen Malabika , Thomas Sufi M. , Sahu Anirban , Cassell Andre , Chen Ching-Shih , Grandis Jennifer R.
Published: April 2023

PDF file, 201KB, Biochemical effect of PDK1 targeting strategies on Akt and p70S6K.
Supplementary Video 1 from Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis
Authors: Francia Giulio , Shaked Yuval , Hashimoto Kae , Sun John , Yin Melissa , Cesta Carolyn , Xu Ping , Man Shan , Hackl Christina , Stewart Julie , Uhlik Mark , Dantzig Anne H. , Foster F. Stuart , Kerbel Robert S.
Published: April 2023

AVI file - 5.8MB
Supplementary Table 1 from EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
Authors: Arcila Maria E. , Nafa Khedoudja , Chaft Jamie E. , Rekhtman Natasha , Lau Christopher , Reva Boris A. , Zakowski Maureen F. , Kris Mark G. , Ladanyi Marc
Published: April 2023

PDF file - 76K, Comprehensive list of mutations tested by mass spectrometry (Sequenom)
Supplementary Table 2 from YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
Authors: Kumar Bhavna , Yadav Arti , Lang James C. , Cipolla Michael J. , Schmitt Alessandra C. , Arradaza Nicole , Teknos Theodoros N. , Kumar Pawan
Published: April 2023

PDF file, 2045KB, Patient tumor characteristics (Group 2).
Supplementary Table 1 from YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
Authors: Kumar Bhavna , Yadav Arti , Lang James C. , Cipolla Michael J. , Schmitt Alessandra C. , Arradaza Nicole , Teknos Theodoros N. , Kumar Pawan
Published: April 2023

PDF file, 34KB, Patient tumor characteristics (Group 1).
Supplementary Figure 4 from Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts
Authors: Anbalagan Muralidharan , Ali Alaa , Jones Ryan K. , Marsden Carolyn G. , Sheng Mei , Carrier Latonya , Bu Yahao , Hangauer David , Rowan Brian G.
Published: April 2023

PDF file, 341K, Alpha tubulin immunoifluorescence assay was performed in MDA-MB-231 cells treated with KX-01. Migration and invasion assay was performed in MDA-MB-231 cells on treatment with KX-01.
Supplementary Figure 5 from RETRACTED: Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Authors: Lee Hae-June , Yoon Changhwan , Schmidt Benjamin , Park Do Joong , Zhang Alexia Y. , Erkizan Hayriye V. , Toretsky Jeffrey A. , Kirsch David G. , Yoon Sam S.
Published: April 2023

PDF - 65KB, Growth of SK-N-MC flank tumors in athymic nude mice treated with 12-15 Gy.
Supplementary Figure 4 from RETRACTED: Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Authors: Lee Hae-June , Yoon Changhwan , Schmidt Benjamin , Park Do Joong , Zhang Alexia Y. , Erkizan Hayriye V. , Toretsky Jeffrey A. , Kirsch David G. , Yoon Sam S.
Published: April 2023

PDF - 198KB, Pictures of clonogenic survival assay for shA673-1C cells treated with olaparib and radiation.
Supplementary Figure 1 from RETRACTED: Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Authors: Lee Hae-June , Yoon Changhwan , Schmidt Benjamin , Park Do Joong , Zhang Alexia Y. , Erkizan Hayriye V. , Toretsky Jeffrey A. , Kirsch David G. , Yoon Sam S.
Published: April 2023

PDF - 32KB, Chemical structure of olaparib
Supplementary Table 1 from Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States
Authors: Wakatsuki Takeru , LaBonte Melissa J. , Bohanes Pierre O. , Zhang Wu , Yang Dongyun , Azuma Mizutomo , Barzi Afsaneh , Ning Yan , Loupakis Fotios , Saadat Siamak , Volz Nico , Stintzing Sebastian , El-Khoueiry Rita , Koizumi Wasaburo , Watanabe Masahiko , Shah Manish , Stebbing Justin , Giamas Georgios , Lenz Heinz-Josef
Published: April 2023

PDF - 85K, Table breakdown comparing the location of the primary tumor (GEJ or stomach) in males and females between the Japanese and US cohorts.
Supplementary Table 1 from Smoking Induces Epithelial-to-Mesenchymal Transition in Non–Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin
Authors: Nagathihalli Nagaraj S. , Massion Pierre P. , Gonzalez Adriana L. , Lu Pengcheng , Datta Pran K.
Published: April 2023

XLS file, 157K, Clinical characteristics of the population with lung cancer.
Supplementary Methods and Figure Legend from Smoking Induces Epithelial-to-Mesenchymal Transition in Non–Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin
Authors: Nagathihalli Nagaraj S. , Massion Pierre P. , Gonzalez Adriana L. , Lu Pengcheng , Datta Pran K.
Published: April 2023

PDF file, 103K.
Supplementary Figure 1 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Authors: Kuruma Hidetoshi , Matsumoto Hiroaki , Shiota Masaki , Bishop Jennifer , Lamoureux Francois , Thomas Christian , Briere David , Los Gerrit , Gleave Martin , Fanjul Andrea , Zoubeidi Amina
Published: April 2023

PDF, 1.4MB, Generation of MDV3100 resistant tumors and cell line MR49F
Supplementary Figure 3 from Induction of Endoplasmic Reticulum Stress by Sorafenib and Activation of NF-κB by Lestaurtinib as a Novel Resistance Mechanism in Hodgkin Lymphoma Cell Lines
Authors: Holz Meike Stefanie , Janning Angela , Renné Christoph , Gattenlöhner Stefan , Spieker Tilmann , Bräuninger Andreas
Published: April 2023

PDF file - 322K, Supplementary Figure S3. Effect of lestaurtinib and sorafenib combined with conventional chemotherapeutic drugs.
Supplementary Figure 2 from Induction of Endoplasmic Reticulum Stress by Sorafenib and Activation of NF-κB by Lestaurtinib as a Novel Resistance Mechanism in Hodgkin Lymphoma Cell Lines
Authors: Holz Meike Stefanie , Janning Angela , Renné Christoph , Gattenlöhner Stefan , Spieker Tilmann , Bräuninger Andreas
Published: April 2023

PDF file - 29K, Supplementary Figure S2. Effect of lestaurtinib treatment on TNFSF8 mRNA expression in HRS and ALCL cell lines.
Supplementary Figures from Receptor-Directed Chimeric Toxins Created by Sortase-Mediated Protein Fusion
Authors: McCluskey Andrew J. , Collier R. John
Published: April 2023

PDF file, 6050K, SrtA ligation reactions displayed on full length SDS-PAGE gels stained by coomassie blue.
Supplementary Figure 1 from Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation
Authors: Bitterman Peter B. , Polunovsky Vitaly A.
Published: April 2023

PDF file - 32K, Recognition of capped mRNA for translation initiation by the complex eIF4F. The eukaryotic translation initiation factor 4E (eIF4E), a 25 kDa phosphoprotein which directly contact to the cap structure, exists either as a monomer or as a subunit of the translation initiation complex eIF4F. When bound to capped messages, eIF4E control post-transcriptional gene expression in the nucleus, where it facilitates the nuclear export of some mRNAs, and in the cytoplasm, where it selectively activates mRNAs for their recruitment to ribosomes. The trimolecular complex eIF4F is essential for recruitment of capped transcripts to ribosomes and subsequent ribosome scanning. It consists of translational factors eIF4E, eIF4G and eIF4A and for the eIF4A cofactor eIF4B. There are two isoforms of translation initiation factor 4G, eIF4GI and eIF4GII that serve a docking function, with the amino terminal half binding to eIF4E, and the C-terminal half binding to eIF4A. The eIF4G family proteins also have recognition sites for several other peptides including for the poly (A) binding protein (PARP), which facilitates circularization of the eIF4F-mRNA complex. Translation initiation factor 4A functions as an ATP requiring helicase by unwinding the 5' region
Supplementary Figure 1 Legend from Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation
Authors: Bitterman Peter B. , Polunovsky Vitaly A.
Published: April 2023

PDF file - 59K, Recognition of the cap
Supplementary Figure Legend from An Optical Probe for Noninvasive Molecular Imaging of Orthotopic Brain Tumors Overexpressing Epidermal Growth Factor Receptor
Authors: Agnes Richard S. , Broome Ann-Marie , Wang Jing , Verma Anjali , Lavik Kari , Basilion James P.
Published: April 2023

PDF file, 83K.
Supplementary Table 1 from Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
Authors: Wainberg Zev A. , Anghel Adrian , Rogers Amy M. , Desai Amrita J. , Kalous Ondrej , Conklin Dylan , Ayala Raul , O'Brien Neil A. , Quadt Cornelia , Akimov Mikhail , Slamon Dennis J. , Finn Richard S.
Published: April 2023

Supplementary Table 1 PDF file - 69K, NVP-AUY922 IC50 concentrations and response to trastuzumab in HER2 amplified breast cancer cell lines
Supplementary Table 1 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
Authors: Pavlicek Adam , Lira Maruja E. , Lee Nathan V. , Ching Keith A. , Ye Jingjing , Cao Joan , Garza Scott J. , Hook Kenneth E. , Ozeck Mark , Shi Stephanie T. , Yuan Jing , Zheng Xianxian , Rejto Paul A. , Kan Julie L.C. , Christensen James G.
Published: April 2023

PDF file - 20K, Gene notations and ABI assay identifiers.
Supplementary Figure 2 from Targeting Interleukin-4 Receptor α with Hybrid Peptide for Effective Cancer Therapy
Authors: Yang Liying , Horibe Tomohisa , Kohno Masayuki , Haramoto Mari , Ohara Koji , Puri Raj K. , Kawakami Koji
Published: April 2023

PDF file - 3.5MB
Supplementary Figure 1 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
Authors: Pavlicek Adam , Lira Maruja E. , Lee Nathan V. , Ching Keith A. , Ye Jingjing , Cao Joan , Garza Scott J. , Hook Kenneth E. , Ozeck Mark , Shi Stephanie T. , Yuan Jing , Zheng Xianxian , Rejto Paul A. , Kan Julie L.C. , Christensen James G.
Published: April 2023

PDF file - 266K, Single agent and combination activity of figitumumab and correlation of combination synergy with the genetic status of major cancer drivers or RNA expression of cancer drivers and IGF pathway alterations.
Supplementary Figure 4 from Inducible Silencing of Protein Kinase D3 Inhibits Secretion of Tumor-Promoting Factors in Prostate Cancer
Authors: LaValle Courtney R. , Zhang Liyong , Xu Shuping , Eiseman Julie L. , Wang Q. Jane
Published: April 2023

PDF file, 59KB, Map of the cytokine antibody array.
Supplementary Figure 3 from Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9
Authors: Petrul Heike M. , Schatz Christoph A. , Kopitz Charlotte C. , Adnane Lila , McCabe Timothy J. , Trail Pamela , Ha Sha , Chang Yong S. , Voznesensky Andrei , Ranges Gerald , Tamburini Paul P.
Published: April 2023

PDF file - 49K, Imaging of CA9-positive (MiaPaCa-2-CA9 transfected) and -negative (MiaPaCa-2 parental cell line) tumors in vivo.
Supplementary Figure 5 from Reversing Effect of Ring Finger Protein 43 Inhibition on Malignant Phenotypes of human Hepatocellular Carcinoma
Authors: Xing Chunyang , Zhou Wuhua , Ding Songming , Xie Haiyang , Zhang Wu , Yang Zhe , Wei Bajin , Chen Kangjie , Su Rong , Cheng Jun , Zheng Shusen , Zhou Lin
Published: April 2023

PDF file - 824K, Knockdown of RNF43 affects the expression of MMPs. HepG2 and SMMC-7721 cells were transfected with indicated siRNAs. Seventy-two hours after transfection, cells were harvest and the expression of specific MMPs was detected by Western blotting.
Supplementary Figure Legend from Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2′-Deoxycytidine in Solid Tumor Cells
Authors: Venturelli Sascha , Berger Alexander , Weiland Timo , Essmann Frank , Waibel Michaela , Nuebling Tina , Häcker Sabine , Schenk Martin , Schulze-Osthoff Klaus , Salih Helmut R. , Fulda Simone , Sipos Bence , Johnstone Ricky W. , Lauer Ulrich M. , Bitzer Michael
Published: April 2023

PDF file - 28K
Supplementary Methods, Table 1, Figures 1-9 from Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
Authors: Greger James G. , Eastman Stephen D. , Zhang Vivian , Bleam Maureen R. , Hughes Ashley M. , Smitheman Kimberly N. , Dickerson Scott H. , Laquerre Sylvie G. , Liu Li , Gilmer Tona M.
Published: April 2023

PDF file - 276K
Supplementary Figure Legend from A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity
Authors: Weldon John E. , Xiang Laiman , Zhang Jingli , Beers Richard , Walker Dawn A. , Onda Masanori , Hassan Raffit , Pastan Ira
Published: April 2023

PDF file - 79K
Supplementary Figure 1 from Cigarette Smoke Induces Aberrant EGF Receptor Activation That Mediates Lung Cancer Development and Resistance to Tyrosine Kinase Inhibitors
Authors: Filosto Simone , Becker Cathleen R. , Goldkorn Tzipora
Published: April 2023

PDF file - 48K
Supplementary Figure Legends from Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo
Authors: Kamat Chandrashekhar D. , Shmueli Ron B. , Connis Nick , Rudin Charles M. , Green Jordan J. , Hann Christine L.
Published: April 2023

PDF file - 50 KB
Supplementary Figure 3 from Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo
Authors: Kamat Chandrashekhar D. , Shmueli Ron B. , Connis Nick , Rudin Charles M. , Green Jordan J. , Hann Christine L.
Published: April 2023

PDF file - 167 KB, The transfection efficiency of 456 polymers is limited by events downstream of binding and uptake.
Supplementary Figure 1 from Poly(β-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo
Authors: Kamat Chandrashekhar D. , Shmueli Ron B. , Connis Nick , Rudin Charles M. , Green Jordan J. , Hann Christine L.
Published: April 2023

PDF file - 86 KB, High-throughput screen of a library of PBAE polymers
Supplementary Table 1 from Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
Authors: Thomas Christian , Lamoureux Francois , Crafter Claire , Davies Barry R. , Beraldi Eliana , Fazli Ladan , Kim Soojin , Thaper Daksh , Gleave Martin E. , Zoubeidi Amina
Published: April 2023

PDF - 107KB, List of antibodies
Supplementary Figure 3 from Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
Authors: Thomas Christian , Lamoureux Francois , Crafter Claire , Davies Barry R. , Beraldi Eliana , Fazli Ladan , Kim Soojin , Thaper Daksh , Gleave Martin E. , Zoubeidi Amina
Published: April 2023

PDF - 164KB, AZD5363 treatment activates the AR and receptor tyrosine kinases pathways
Supplementary Figure 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Authors: Kalous Ondrej , Conklin Dylan , Desai Amrita J. , O'Brien Neil A. , Ginther Charles , Anderson Lee , Cohen David J. , Britten Carolyn D. , Taylor Ian , Christensen James G. , Slamon Dennis J. , Finn Richard S.
Published: April 2023

PDF file, 45K, Dacomitinib response is associated with the total HER2 protein levels in HER2-amplified cell lines.
Supplementary Table 3 from microRNA-9 Targets Matrix Metalloproteinase 14 to Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells
Authors: Zhang Huanyu , Qi Meng , Li Shiwang , Qi Teng , Mei Hong , Huang Kai , Zheng Liduan , Tong Qiangsong
Published: April 2023

PDF file, 23KB, MMP-14 expression in the NB tissues.
Supplementary Table S3 from miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR
Authors: Xu Chuanliang , Zeng Qinsong , Xu Weidong , Jiao Li , Chen Yanqiong , Zhang Zhensheng , Wu Chengyao , Jin Taile , Pan Anyin , Wei Rongchao , Yang Bo , Sun Yinghao
Published: April 2023

PDF file - 65KB, Significantly dysregulated miRNAs in non-invasive BC
Supplementary Table S1 from miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR
Authors: Xu Chuanliang , Zeng Qinsong , Xu Weidong , Jiao Li , Chen Yanqiong , Zhang Zhensheng , Wu Chengyao , Jin Taile , Pan Anyin , Wei Rongchao , Yang Bo , Sun Yinghao
Published: April 2023

PDF file - 117KB, Patient characteristics
Supplementary Table 6 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Authors: Siemeister Gerhard , Lücking Ulrich , Wengner Antje M. , Lienau Philip , Steinke Wolfram , Schatz Christoph , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

PDF file, 93K, Overview on xenograft data.
Supplemental Figure 2 from Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy
Authors: Tyler Paul M. , Servos Mariah M. , de Vries Romy C. , Klebanov Boris , Kashyap Trinayan , Sacham Sharon , Landesman Yosef , Dougan Michael , Dougan Stephanie K.
Published: April 2023

Supplemental Figure 2: IFNÎ³ secretion is impaired by selinexor.
Figure S3 from A Novel Theranostic Strategy for MMP-14–Expressing Glioblastomas Impacts Survival
Authors: Mohanty Suchismita , Chen Zixin , Li Kai , Morais Goreti Ribeiro , Klockow Jessica , Yerneni Ketan , Pisani Laura , Chin Frederick T. , Mitra Siddharta , Cheshier Samuel , Chang Edwin , Gambhir Sanjiv Sam , Rao Jianghong , Loadman Paul M. , Falconer Robert A. , Daldrup-Link Heike E.
Published: April 2023

In vivo tumorigenic assay for GIC derived from pcGBM39
Table S1 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
Authors: Leconet Wilhem , Liu He , Guo Ming , Le Lamer-Déchamps Sophie , Molinier Charlotte , Kim Sae , Vrlinic Tjasa , Oster Murielle , Liu Fang , Navarro Vicente , Batra Jaspreet S. , Noriega Adolfo Lopez , Grizot Sylvestre , Bander Neil H.
Published: April 2023

BiJ591 solution composition before spray-drying
Figure S1 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
Authors: Leconet Wilhem , Liu He , Guo Ming , Le Lamer-Déchamps Sophie , Molinier Charlotte , Kim Sae , Vrlinic Tjasa , Oster Murielle , Liu Fang , Navarro Vicente , Batra Jaspreet S. , Noriega Adolfo Lopez , Grizot Sylvestre , Bander Neil H.
Published: April 2023

Analysis of purified BiJ591 by SEC-HPLC
Supplementary Figure S5 from Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model
Authors: Stallons Tania A. Rozgaja , Saidi Amal , Tworowska Izabela , Delpassand Ebrahim S. , Torgue Julien J.
Published: April 2023

At 20 µCi, there were relatively mild and reversible effects on weight gain (Panel A) and leukocyte counts (Panel B). Initially, animals in the 40µCi treatment group lost body weight and presented the strongest leukopenia but began to recover by 10 and 30 days, respectively, post injection. By Day 30, all groups were within reference ranges for hematologic parameters. As of the Day 90 timepoint, there have been no severe toxicological effects observed. Based on the study findings, the dose of 10 µCi was considered a no-observable adverse effect limit (NOAEL) dose and an HNSTD of 20μCi was determined.
Supplementary Figure S4 from Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model
Authors: Stallons Tania A. Rozgaja , Saidi Amal , Tworowska Izabela , Delpassand Ebrahim S. , Torgue Julien J.
Published: April 2023

Alpha imaging of tumors treated with 212Pb-DOTAMTATE showed homogenous distribution of the drug at all tumor sizes up to 1500mm3 (Panel B). Kidney protection agent consisting of 35mg lysine are effective at reducing kidney uptake of 212Pb-DOTAMTATE but do not have an impact on 212Pb-DOTAMTATE uptake by AR42J tumors (Panel B).
Supplementary Fig. S3 from TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models
Authors: Yoshimura Chihoko , Muraoka Hiromi , Ochiiwa Hiroaki , Tsuji Shingo , Hashimoto Akihiro , Kazuno Hiromi , Nakagawa Fumio , Komiya Yu , Suzuki Satoshi , Takenaka Toru , Kumazaki Masafumi , Fujita Naoya , Mizutani Takashi , Ohkubo Shuichi
Published: April 2023

Supplementary Figure S3. TAS4464 is effective against THP-1 cells and HCT116 cells. In vitro pharmacodynamic activity of TAS4464 on HCT116 cells and on THP-1 cells (A). (B,C ) Time dependent cytotoxicity of TAS4464. THP-1 cells and HCT116 cells were treated with TAS4464 for indicated time and then washed out and cultured in drug-free medium. Percentage of growth was evaluated at 72 hours after the beginning of each exposure.
Supplemental Figure 8 from Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma
Authors: Gowda Raghavendra , Kardos Gregory , Sharma Arati , Singh Sanjay , Robertson Gavin P.
Published: April 2023

Supplemental Figure 8. Caspase-3/7 activity in cell lysates following 24 hour CelePlum-777 treatment.
Figure S3 from Itraconazole-Induced Inhibition on Human Esophageal Cancer Cell Growth Requires AMPK Activation
Authors: Chen Min-Bin , Liu Yuan-Yuan , Xing Zhao-Yu , Zhang Zhi-Qing , Jiang Qin , Lu Pei-Hua , Cao Cong
Published: April 2023

Figure S3. Stable Eca-109 cells (5Ã-106 cells per mouse), expressing scramble control shRNA ("shRNA-C") or AMPKÎ±1 shRNA ("sh-AMPKÎ±1"), were inoculated (s.c. injection) to the SCID mice, with 8 mice per group. When the volume of each tumor was around 150 mm3 ("D0"), the recording started. The tumor volume (A) and the mice body weight (D) were recorded every 7 days; Daily tumor growth (in mm3 per day) was calculated (B); At day-42, tumors were separated and weighted (C). At experimental Day-8, one Eca-109 tumor per group was isolated, expression of listed proteins were tested by a Western blotting assay (E).
Supplementary Figures from A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells
Authors: Maekawa Hisatsugu , Miyoshi Hiroyuki , Yamaura Tadayoshi , Itatani Yoshiro , Kawada Kenji , Sakai Yoshiharu , Taketo M. Mark
Published: April 2023

Supplementary Figures S1 Mouse preparation efficiencies for drug sensitivity tests with PDXs (top) and PDSXs (bottom). Supplementary Figures S2 Histopathology of the primary (top), PDX (middle), and PDSX (bottom) tumors analyzed by H&E staining (left), and by IHC for MUC2 (center) and CDX2 (right). Supplementary Figures S3 Growth of the xenograft tumors as PDXs and PDSXs derived from the same cancer (HC1T). Supplementary Figures S4 Comparison between PDXs and PDSXs in drug-dosing tests (with HC5T, HC16T, and HC17T). Supplementary Figures S5 Reproducibility of PDSXs in drug dosing tests (with HC5T and HC17T). Supplementary Figures S6 Clinical course of the patient during the chemotherapy who had colon cancer HC59T, and its drug responses as PDSXs. Supplementary Figures S7 Clinical course of the patient during the chemotherapy who had colon cancer HC73T, and its drug responses as PDSXs. Supplementary Figures S8 Clinical course of the patient during the chemotherapy who had colon cancer HC70T, and its drug response as PDSXs. Supplementary Figures S9 Clinical course of the patient during chemotherapy who had colon cancer HC5T, and its drug response as PDSXs. Supplementary Figures S10 Correlations of the PDSX dosing data (T/C and TGI values) with the patients'' clinical responses. Supplementary Figures S11 Time line comparison in preparation of the drug-dosing test-mice that carried PDXs (top) and PDSXs (bottom).
Supplementary Fig S5 from TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
Authors: Ito Kimihiro , Nishio Makoto , Kato Masanori , Murakami Haruyasu , Aoyagi Yoshimi , Ohe Yuichiro , Okayama Takashige , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Gotaro , Nonoshita Katsumasa , Ito Satoru , Matsuo Kenichi , Miyadera Kazutaka
Published: April 2023

Supplementary Fig. S5 shows anti-tumor effect of TAS-121 in HCC827 xenograft mouse models.
Supplementary Fig S2 from TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
Authors: Ito Kimihiro , Nishio Makoto , Kato Masanori , Murakami Haruyasu , Aoyagi Yoshimi , Ohe Yuichiro , Okayama Takashige , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Gotaro , Nonoshita Katsumasa , Ito Satoru , Matsuo Kenichi , Miyadera Kazutaka
Published: April 2023

Supplementary Fig. S2 shows inhibitory activity of TAS-121 for ERBB family kinases.
Supplementary Figures 1-8 from Development of Therapeutic Anti-JAGGED1 Antibodies for Cancer Therapy
Authors: Masiero Massimo , Li Demin , Whiteman Pat , Bentley Carol , Greig Jenny , Hassanali Tasneem , Watts Sarah , Stribbling Stephen , Yates Jenna , Bealing Ellen , Li Ji-Liang , Chillakuri Chandramouli , Sheppard Devon , Serres Sébastien , Sarmiento-Soto Manuel , Larkin James , Sibson Nicola R. , Handford Penny A. , Harris Adrian L. , Banham Alison H.
Published: April 2023

1: JAG1 antibody characterization. 2: antibody inhibition of JAG1 mediated Notch signalling in tumor cell lines. 3: antibody inhibition of JAG1 signalling in vascular cells. 4: antibody inhibition of JAG1 signalling in HUVEC-HUVSMC co-culture. 5: effect of anti-Notch pathway treatment on MDA-MB231 2D growth and J1-65D titration and effect on 3D growth and gene expression. 6: J1-65D treatment of established OVCAR3 xenograft. 7: JAG1 antibodies cross-reactivity with rat Jag1. 8: anti-JAG1 treatment effect in a rat brain metastasis model.
Supplementary Table Descriptions from Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer
Authors: Naidoo Kalnisha , Wai Patty T. , Maguire Sarah L. , Daley Frances , Haider Syed , Kriplani Divya , Campbell James , Mirza Hasan , Grigoriadis Anita , Tutt Andrew , Moseley Paul M. , Abdel-Fatah Tarek M.A. , Chan Stephen Y.T. , Madhusudan Srinivasan , Rhaka Emad A. , Ellis Ian O. , Lord Christopher J. , Yuan Yinyin , Green Andrew R. , Natrajan Rachael
Published: April 2023

Supplementary table descriptions
Supplementary Figure 8 from Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers
Authors: Disis Mary L. , Corulli Lauren R. , Gad Ekram A. , Koehnlein Marlese R. , Cecil Denise L. , Senter Peter D. , Gardai Shyra J. , Okeley Nicole M.
Published: April 2023

Mean {plus minus} SEM of peripheral cytokines detected in terminal sera collected from untreated (shaded) and 2FF-treated (unshaded) TgMMTV-neu mice. N=6 to 8 per group, *p<0.05.
Supplementary Figure 6 from Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers
Authors: Disis Mary L. , Corulli Lauren R. , Gad Ekram A. , Koehnlein Marlese R. , Cecil Denise L. , Senter Peter D. , Gardai Shyra J. , Okeley Nicole M.
Published: April 2023

Weights were collected from n=7 to 20 TgMMTV-neu mice per group at various times throughout the study; average weight is represented over age of untreated (circle), 20mM 2FF (square) and 50mM 2FF (triangle) treated mice. The solid gray arrow represents end of 50mM 2FF treatment, dashed black arrow represents end of 20mM 2FF treatment.
Supplementary Figure 5 from Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers
Authors: Disis Mary L. , Corulli Lauren R. , Gad Ekram A. , Koehnlein Marlese R. , Cecil Denise L. , Senter Peter D. , Gardai Shyra J. , Okeley Nicole M.
Published: April 2023

Effect of 2FF-treatment on (A) Tumor volume (Mean {plus minus} SEM) over days since implant for mice treated with IgG2b (open circle), anti-CD8 (diamond), 20mM 2FF+IgG2b (closed circle), or 20mM 2FF+anti-CD8 (triangle), n=5 per group; and (B) Tumor volume (Mean {plus minus} SEM) over days since implant for mice treated with IgG2b (open circle), anti-NK (diamond), 20mM 2FF+IgG2b (closed circle), or 20mM 2FF+anti-NK (triangle), n=5 per group ****p<0.0001.
Figure S3 from SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status
Authors: Fujihara Kenji M. , Corrales Benitez Mariana , Cabalag Carlos S. , Zhang Bonnie Z. , Ko Hyun S. , Liu David S. , Simpson Kaylene J. , Haupt Ygal , Lipton Lara , Haupt Sue , Phillips Wayne A. , Clemons Nicholas J.
Published: April 2023

Figure S3 shows extended correlation analysis in haematopoietic and lymphoid, breast and lung cancer cell lines
Supplemental figure 1 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Authors: Kushibiki Toshihiro , Nakamura Toru , Tsuda Masumi , Tsuchikawa Takahiro , Hontani Koji , Inoko Kazuho , Takahashi Mizuna , Asano Toshimichi , Okamura Keisuke , Murakami Soichi , Kurashima Yo , Ebihara Yuma , Noji Takehiro , Nakanishi Yoshitsugu , Tanaka Kimitaka , Maishi Nako , Sasaki Katsunori , Park Woong-Ryeon , Shichinohe Toshiaki , Hida Kyoko , Tanaka Shinya , Hirano Satoshi
Published: April 2023

Supplemental Figure 1 shows, (A) analysis of expression of C16orf74 in C16orf74 stable and MOCK cell lines by qRT-PCR, (B) expression of C16orf74 in C16orf74 stable and MOCK by Western blotting, (C) expression of C16orf74 in C16orf74 stable clonal cell lines by Immunofluorescence. C16orf74 localizes under the cell membrane, and (D) expression of endogenous C16orf74 protein in PK-9 cells shown by Immunofluorescence. Endogenous C16orf74 localizes under the cell membrane.
Supplemental Table 2 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Authors: Kushibiki Toshihiro , Nakamura Toru , Tsuda Masumi , Tsuchikawa Takahiro , Hontani Koji , Inoko Kazuho , Takahashi Mizuna , Asano Toshimichi , Okamura Keisuke , Murakami Soichi , Kurashima Yo , Ebihara Yuma , Noji Takehiro , Nakanishi Yoshitsugu , Tanaka Kimitaka , Maishi Nako , Sasaki Katsunori , Park Woong-Ryeon , Shichinohe Toshiaki , Hida Kyoko , Tanaka Shinya , Hirano Satoshi
Published: April 2023

The primary antibodies and dilutions for Western blot analysis